Company Description
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases.
The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients.
Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
| Country | United States |
| IPO Date | Feb 4, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Dr. Eric E. Poma Ph.D. |
Contact Details
Address: 9301 Amberglen Boulevard Austin, Texas United States | |
| Website | https://www.mtem.com |
Stock Details
| Ticker Symbol | MTEM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001183765 |
| CUSIP Number | 608550109 |
| ISIN Number | US6085502085 |
| Employer ID | 94-3409596 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric E. Poma Ph.D. | Interim Chief Financial Officer, Treasurer, Principal Acc. Officer, Chief Executive Officer, Chief Scientific Officer & Director |
| Kristen Quigley B.A. | Chief Operating Officer |
| Dr. Chris Moore Ph.D. | Senior Vice President and Head of Preclinical Development & Translational Medicine |
| Dr. Grace Kim | Chief Strategy Officer & Head of IR |
| Dr. Joseph Phillips Ph.D. | Senior Vice President & Head of CMC Development |
| Dr. Michelle Iwamoto-Fan J.D., Ph.D. | Senior Vice President & General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 02, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 04, 2024 | DEFA14A | Filing |
| Dec 04, 2024 | 8-K | Current Report |
| Dec 04, 2024 | 8-K | Current Report |
| Nov 26, 2024 | DEFA14A | Filing |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 18, 2024 | 4 | Filing |
| Nov 15, 2024 | NT 10-Q | Filing |